WO2005065647A3 - Drug granule coatings that impart smear resistance during mechanical compression - Google Patents

Drug granule coatings that impart smear resistance during mechanical compression Download PDF

Info

Publication number
WO2005065647A3
WO2005065647A3 PCT/US2004/043931 US2004043931W WO2005065647A3 WO 2005065647 A3 WO2005065647 A3 WO 2005065647A3 US 2004043931 W US2004043931 W US 2004043931W WO 2005065647 A3 WO2005065647 A3 WO 2005065647A3
Authority
WO
WIPO (PCT)
Prior art keywords
disclosed
substrate
mechanical compression
coating
granule
Prior art date
Application number
PCT/US2004/043931
Other languages
French (fr)
Other versions
WO2005065647A2 (en
Inventor
David Edgren
Alya Khan
Abdul Majid Qureshi
James Ergun
Satishkumar Ramachandran
Noymi Yam
Original Assignee
Alza Corp Inc
David Edgren
Alya Khan
Abdul Majid Qureshi
James Ergun
Satishkumar Ramachandran
Noymi Yam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp Inc, David Edgren, Alya Khan, Abdul Majid Qureshi, James Ergun, Satishkumar Ramachandran, Noymi Yam filed Critical Alza Corp Inc
Priority to CA002551825A priority Critical patent/CA2551825A1/en
Priority to JP2006547568A priority patent/JP2007517062A/en
Priority to EP04815921A priority patent/EP1701707A2/en
Priority to MXPA06007511A priority patent/MXPA06007511A/en
Priority to AU2004312083A priority patent/AU2004312083A1/en
Publication of WO2005065647A2 publication Critical patent/WO2005065647A2/en
Publication of WO2005065647A3 publication Critical patent/WO2005065647A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

A drug formulation is disclosed comprising granules having a substrate and a coating, said granule substrate comprising a solubilizing surfactant or a low solubility therapeutic drug, or both, and said granule coating comprising a hydrophilic polymer. Also disclosed is a drug formulation consisting of a tablet core made by mechanical compression, wherein said tablet core comprises granules having a substrate and a coating, said granule substrate comprising a solubilizing surfactant or a low solubility therapeutic drug, or both, and said granule coating comprising a hydrophilic polymer. Also disclosed is a dosage form for oral administration of topiramate, comprising a tablet core and an osmotic delivery system. Methods for controlling topiramate release patterns by altering the composition of the topiramate dosage form are also disclosed.
PCT/US2004/043931 2003-12-29 2004-12-28 Drug granule coatings that impart smear resistance during mechanical compression WO2005065647A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002551825A CA2551825A1 (en) 2003-12-29 2004-12-28 Drug granule coatings that impart smear resistance during mechanical compression
JP2006547568A JP2007517062A (en) 2003-12-29 2004-12-28 Coating of drug granules giving adhesion resistance during mechanical compression
EP04815921A EP1701707A2 (en) 2003-12-29 2004-12-28 Drug granule coatings that impart smear resistance during mechanical compression
MXPA06007511A MXPA06007511A (en) 2003-12-29 2004-12-28 Drug granule coatings that impart smear resistance during mechanical compression.
AU2004312083A AU2004312083A1 (en) 2003-12-29 2004-12-28 Drug granule coatings that impart smear resistance during mechanical compression

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53347003P 2003-12-29 2003-12-29
US53311203P 2003-12-29 2003-12-29
US60/533,112 2003-12-29
US60/533,470 2003-12-29

Publications (2)

Publication Number Publication Date
WO2005065647A2 WO2005065647A2 (en) 2005-07-21
WO2005065647A3 true WO2005065647A3 (en) 2005-12-08

Family

ID=34752987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/043931 WO2005065647A2 (en) 2003-12-29 2004-12-28 Drug granule coatings that impart smear resistance during mechanical compression

Country Status (6)

Country Link
EP (1) EP1701707A2 (en)
JP (1) JP2007517062A (en)
AU (1) AU2004312083A1 (en)
CA (1) CA2551825A1 (en)
MX (1) MXPA06007511A (en)
WO (1) WO2005065647A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007169273A (en) * 2005-11-28 2007-07-05 Takeda Chem Ind Ltd Medicinal preparation of which attachment to pestle is improved
JP5527921B2 (en) * 2006-12-22 2014-06-25 エスエス製薬株式会社 Oral solid composition concealing bitterness
DE102012014848A1 (en) * 2012-07-27 2012-10-31 Heilerde-Gesellschaft Luvos Just GmbH & Co. KG Healing clay-composition present as non-coated or as coated granules, comprises healing clay and binding agent containing at least one water soluble polymer e.g. starch, tragacanth or cellulose acetate, cellulose ether
CA2906172C (en) 2013-03-15 2021-12-21 Aprecia Pharmaceuticals Company Rapidly dispersible dosage form of topiramate
EP3960240B1 (en) 2019-04-25 2024-03-27 Fuji Pharma Co., Ltd. Pharmaceutical preparation and method for producing same
EP4238565A1 (en) 2020-10-28 2023-09-06 KinoPharma, Inc. Pharmaceutical composition for preventing or treating viral perivaginal disease

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044581A2 (en) * 1998-03-04 1999-09-10 Ortho-Mcneil Pharmaceutical, Inc. Pharmaceutical composition of topiramate
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
WO2004002447A2 (en) * 2002-06-26 2004-01-08 Alza Corporation Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
WO2004010970A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
WO2005016306A2 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
WO2005020959A2 (en) * 2003-09-02 2005-03-10 Alza Corporation Novel drug compositions and dosage forms of topiramate
WO2005063206A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044581A2 (en) * 1998-03-04 1999-09-10 Ortho-Mcneil Pharmaceutical, Inc. Pharmaceutical composition of topiramate
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
WO2004002447A2 (en) * 2002-06-26 2004-01-08 Alza Corporation Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
WO2004010970A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
WO2005016306A2 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
WO2005020959A2 (en) * 2003-09-02 2005-03-10 Alza Corporation Novel drug compositions and dosage forms of topiramate
WO2005063206A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery

Also Published As

Publication number Publication date
MXPA06007511A (en) 2009-06-10
JP2007517062A (en) 2007-06-28
EP1701707A2 (en) 2006-09-20
AU2004312083A1 (en) 2005-07-21
WO2005065647A2 (en) 2005-07-21
CA2551825A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
CA2391406C (en) Multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients
AU777870B2 (en) Film preparation for biphasic release of pharmacologically active or other substances
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
CA2446712C (en) System for osmotic delivery of pharmaceutically active agents
WO2003028660A3 (en) Drug delivery devices and methods
WO2002053100A3 (en) Pharmaceutical dosage form for oral administration of low molecular weight heparin
WO2007048233A1 (en) Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
WO2005117843A3 (en) Sustained release preparations
WO2006039499A3 (en) Method for improving the biovailability of orally delivered therapeutics
WO2002030398A3 (en) Delayed release pharmaceutical formulations
BR0103033A (en) Pharmaceutical particles of masked flavor
MXPA03012041A (en) Gastric retention controlled drug delivery system.
WO2008011177A3 (en) Medicinal delivery system and related methods
KR20130086128A (en) Easily dosable solid preparation
AU2001291526A1 (en) Sustained release composition containing clarithromycin
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
AU2004315136B2 (en) Extended release coated microtablets of venlafaxine hydrochloride
EP1238662A3 (en) Method for manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules
WO2003074033A8 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
WO2007034287A3 (en) Oramucosal pharmaceutical dosage form
WO2005065647A3 (en) Drug granule coatings that impart smear resistance during mechanical compression
WO2004078111A3 (en) Extended release minocycline compositions and processes for their preparation
WO2007144902A8 (en) Chewable bilayer tablet formulation
WO2003096874A3 (en) Coated sustained release tablets of a hygroscopic compound for once-a-day therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 547534

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004312083

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004312083

Country of ref document: AU

Date of ref document: 20041228

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004312083

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2551825

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/007511

Country of ref document: MX

Ref document number: 2004815921

Country of ref document: EP

Ref document number: 2006547568

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWP Wipo information: published in national office

Ref document number: 2004815921

Country of ref document: EP